Published in Eur J Haematol on April 01, 2006
Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One (2009) 0.88
Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol (2014) 0.81
Functional analysis of -351 interleukin-9 promoter polymorphism reveals an activator controlled by NF-kappaB. Genes Immun (2009) 0.78
Evaluation of the T helper 17 cell specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency. J Res Med Sci (2014) 0.76
Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica (2016) 0.75
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum (2006) 5.03
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood (2002) 3.00
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood (2007) 2.25
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet (2002) 1.97
Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst (2007) 1.87
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol (2012) 1.87
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood (2004) 1.77
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma (2008) 1.53
Dealing with sickness certification - a survey of problems and strategies among general practitioners and orthopaedic surgeons. BMC Public Health (2007) 1.51
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol (2012) 1.48
Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res (2007) 1.48
Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum (2003) 1.46
Histidine decarboxylase, a pyridoxal phosphate-dependent enzyme, is an autoantigen of gastric enterochromaffin-like cells. J Clin Endocrinol Metab (2003) 1.46
Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity (2011) 1.46
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res (2007) 1.45
[The mast cell--both evil and good. Time to reconsider the role of the mast cell in health and disease]. Lakartidningen (2009) 1.38
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol (2005) 1.31
Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol (2012) 1.27
Hepatitis C infection and risk of malignant lymphoma. Int J Cancer (2008) 1.27
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol (2002) 1.23
Sickness-certification practice in different clinical settings; a survey of all physicians in a country. BMC Public Health (2010) 1.23
Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood (2005) 1.22
Mast cells as sensors of cell injury through IL-33 recognition. J Immunol (2011) 1.21
Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest (2006) 1.18
The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood (2007) 1.18
Frequency and severity of problems that general practitioners experience regarding sickness certification. Scand J Prim Health Care (2011) 1.14
DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med (2013) 1.12
Excessive use of rapid tests in respiratory tract infections in Swedish primary health care. Scand J Infect Dis (2004) 1.10
Types of morbidity and categories of patients in a Swedish county. Applying the Johns Hopkins Adjusted Clinical Groups System to encounter data in primary health care. Scand J Prim Health Care (2004) 1.08
Nutrient intake and risk of non-Hodgkin's lymphoma. Am J Epidemiol (2006) 1.06
Is there a role for mast cells in psoriasis? Arch Dermatol Res (2008) 1.06
Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer (2003) 1.04
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood (2003) 1.00
Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. Am J Hum Genet (2013) 1.00
Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum (2006) 0.99
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer (2010) 0.99
Expression of 15-lipoxygenase type-1 in human mast cells. Biochim Biophys Acta (2007) 0.99
Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol (2002) 0.99
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol (2014) 0.98
Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma - pathological development and restitution. Acta Oncol (2014) 0.98
Mast cells as regulators of skin inflammation and immunity. Acta Derm Venereol (2011) 0.98
Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol (2011) 0.98
Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem Biophys Res Commun (2002) 0.97
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res (2008) 0.97
Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy (2012) 0.97
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology (2003) 0.97
Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat (2008) 0.97
Collection and retrieval of structured clinical data from electronic patient records in general practice. A first-phase study to create a health care database for research and quality assessment. Scand J Prim Health Care (2004) 0.96
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology (2010) 0.96
TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res (2010) 0.96
Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood (2012) 0.96
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res (2011) 0.95
FcepsilonRI aggregation promotes survival of connective tissue-like mast cells but not mucosal-like mast cells. J Immunol (2007) 0.95
A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma (2002) 0.95
HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol (2013) 0.95
NFAT but not NF-kappaB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells. Blood (2008) 0.94
Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol (2002) 0.93
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol (2009) 0.93
Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis (2009) 0.93
TLR2/MyD88-dependent and -independent activation of mast cell IgE responses by the skin commensal yeast Malassezia sympodialis. J Immunol (2009) 0.92
Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res (2010) 0.92
Mast Cells Respond to Cell Injury through the Recognition of IL-33. Front Immunol (2012) 0.91
Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. J Exp Med (2012) 0.91
Chemokine receptor expression by mast cells. Chem Immunol Allergy (2005) 0.91
Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. Rheumatology (Oxford) (2009) 0.91
Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis (2005) 0.90